SVCP
RGNX icon

Silicon Valley Capital Partners’s Regenxbio RGNX Stock Holding History

Silicon Valley Capital Partners’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101 Buy
+12
New +$126 ﹤0.01% 423

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silicon Valley Capital Partners's RGNX Position: Q1 2026 in Review

Silicon Valley Capital Partners opened a new position in Regenxbio (RGNX) in Q1 2026: 12 shares worth $101. The stake represents ﹤0.01% of the portfolio and ranks #423 among its holdings.

178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Silicon Valley Capital Partners held 12 shares of Regenxbio worth $101 as of Q1 2026.
  • Regenxbio was a new Silicon Valley Capital Partners position in Q1 2026.
  • Regenxbio made up ﹤0.01% of Silicon Valley Capital Partners's portfolio in Q1 2026, its #423 holding.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Silicon Valley Capital Partners's 13F filing for Q1 2026, filed 19 May 2026.